In the last decade, pharmaceutical companies have seen rapid changes in the market environment for their new brand launches. While austerity measures in many countries are increasing local and national hurdles for market access, drug launches are becoming more numerous, smaller, and more competitive. It has never been more important for pharmaceutical companies to master the art of launching new products.


Register here for a course, it’s not too late yet!

The Content

The course content builds on the expertise and experience that the experts have accumulated over the last 15 years in advising and implementing major product launches in EMEA across major therapy areas: Oncology (incl. Immunotherapy), Immunology, CNS, CVS and Metabolic Disorders. It covers all concepts and evidence-based tools for effective strategic decision- making and planning in the process up to launch, with a focus on what will determine the brand’s commercial success.

The faculty combines academic rigour with best practice within big pharma. Kurt Arco was with MSD (Merck & Co) until recently, where he led several major product launches in many geographical areas and contributed to, and piloted, major marketing & sales excellence projects.

Their company Trilations is a strategy consultancy agency that works closely with most of the major pharmaceutical and medical device companies in more than 40 countries worldwide (e.g. Johnson & Johnson, MSD, Roche, Pfizer, Boston Scientific, …).

The dates

5 – 6 October 2021, live online

16 – 17 December 2021, live online

Our dedicated team of market strategy experts combines in-depth industry knowledge, advanced analytic & team mobilization skills to deliver high added value in all your analytical and strategic projects.
Joeri De Haes Director Japan & Asia Pacific
Our aim is to be the preferred business partner of our customers, by providing innovative, added value services via engaged consultants.
Johan Vermeiren CEO

Related content

Spring conference series

Read more